Evidence map›Paper›PMID 33848831›Full record

ArticleThe Journal of surgical research2021

A Novel Color-Coded Liver Metastasis Mouse Model to Distinguish Tumor and Adjacent Liver Segment.

Hiroto Nishino, Hannah M Hollandsworth, Siamak Amirfakhri, Yoshihiko Tashiro, Jun Yamamoto, Michael A Turner, Thinzar M Lwin, Bernhard B Singer, Robert M Hoffman, Michael Bouvet

Open access · greenAbstract read
In one paragraph

Article in The Journal of surgical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Hiroto NishinoDepartment of Surgery, University of California San Diego, San Diego, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California; AntiCancer, Inc., San Diego, California; Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hannah M HollandsworthDepartment of Surgery, University of California San Diego, San Diego, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California.
Siamak AmirfakhriDepartment of Surgery, University of California San Diego, San Diego, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California.
Yoshihiko TashiroDepartment of Surgery, University of California San Diego, San Diego, California; AntiCancer, Inc., San Diego, California.
Jun YamamotoDepartment of Surgery, University of California San Diego, San Diego, California; AntiCancer, Inc., San Diego, California.
Michael A TurnerDepartment of Surgery, University of California San Diego, San Diego, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California.
Thinzar M LwinDepartment of Surgery, University of California San Diego, San Diego, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California.
Bernhard B SingerInstitute of Anatomy, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Robert M HoffmanDepartment of Surgery, University of California San Diego, San Diego, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California; AntiCancer, Inc., San Diego, California.
Michael BouvetDepartment of Surgery, University of California San Diego, San Diego, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California. Electronic address: mbouvet@ucsd.edu.
University of California San Diego · USKyoto University · JPUniversity of Duisburg-Essen · DE

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Development of Near Infrared Fluorescence-Guided Surgical Navigation and Tumor Specific Photoimmunotherapy for Improved Outcomes for GI CancersI01BX003856 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BOUVET, MICHAEL · 2018 to 2022
–
CMA- Marker-assisted prevention and risk stratification (MAPRS): Mucin signatures and molecular imaging for the early detection of colorectal cancer.I01BX004494 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BOUVET, MICHAEL · 2020 to 2023
–
BLRD VA I01 BX003856BLRD VA I01 BX004494NCI NIH HHS T32 CA121938
6 · The paper itself

Abstract

backgroundIt is difficult to distinguish between a tumor and its liver segment with traditional use of indocyanine green (ICG) alone. In the present study, a method was used to limit ICG to the liver segment adjacent to a tumor. A spectrally-distinct fluorescently-labeled tumor-specific antibody against human carcinoembryonic antigen-related cell-adhesion molecules was used to label the metastatic tumor in a patient-derived orthotopic xenograft mouse model to enable color-coded visualization and distinction of a colon-cancer liver metastases and its adjacent liver segment. MATERIALS AND

methodsNude mice received surgical orthotopic implantation in the liver of colon-cancer liver metastases derived from two patients. An anti- carcinoembryonic antigen-related cell-adhesion molecules monoclonal antibody (mAb 6G5j) was conjugated to a near-infrared dye IR700DX (6G5j-IR700DX). After three weeks, mice received 6G5j-IR700DX via tail-vein injection 48 hours before surgery. ICG was intravenously injected after ligation of the left or left lateral Glissonean pedicle resulting in labeling of the segment with preserved blood-flow in the liver. Imaging was performed with the Pearl Trilogy and FLARE Imaging Systems.

resultsThe metastatic liver tumor had a clear fluorescence signal due to selective tumor targeting by 6G5j-IR700DX, which was imaged on the 700 nm channel. The adjacent liver segment, with preserved blood-flow in the liver, had a clear fluorescence ICG 800 nm signal, while the left or left lateral segment had no fluorescence signal. Overlay of the images showed clear color-coded differentiation between the tumor fluorescing at 700 nm and the adjacent liver segment fluorescing at 800 nm.

conclusionsColor-coding of a liver tumor and uninvolved liver segment has the potential for improved liver resection.

Indexed as

AnimalsAntibodies, MonoclonalCarcinoembryonic AntigenColonic NeoplasmsColorFluorescent DyesGPI-Linked ProteinsHepatectomyHumansIndocyanine GreenInjections, IntravenousLiverLiver NeoplasmsMiceMolecular ImagingOptical ImagingAntibodies, MonoclonalCarcinoembryonic AntigenCEACAM5 protein, humanFluorescent DyesGPI-Linked ProteinsIndocyanine GreenCEACAMColon cancerColor-coded fluorescence imagingFluorescent tumor-specific antibodyIndocyanine greenLiver metastasesNude mouse model

Identifiers

PMID33848831
PMCPMC8222089
OpenAlexW3154061294

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.